1
NURS 6521N ADVANCED PHARMACOLOGY
Comprehensive Final Exam Study Guide | Original
Practice Questions 2025/2026 Edition
COURSE OVERVIEW & KEY CONTENT AREAS
Advanced Pharmacology for APRNs typically covers:
1. Pharmacokinetics & Pharmacodynamics
2. Autonomic Nervous System Drugs
3. Cardiovascular & Renal Pharmacology
4. Endocrine Pharmacology
5. Anti-Infective Agents
6. Central Nervous System Drugs
7. Oncology & Immunopharmacology
8. Special Populations (Pediatrics, Geriatrics, Pregnancy)
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS
Questions 1-20
1. A 68-year-old patient with cirrhosis and hypoalbuminemia is prescribed a
highly protein-bound medication. The nurse practitioner understands that the
free (active) drug concentration will be:
A. Decreased due to increased protein binding capacity
B. Increased due to reduced albumin available for protein binding
C. Unchanged because protein binding does not affect drug activity
D. Decreased because the liver metabolizes the drug more rapidly
Answer: B
pg. 1
,2
Detailed Rationale: Hypoalbuminemia (low serum albumin) reduces the number
of protein-binding sites available for highly protein-bound drugs (e.g., phenytoin,
warfarin, valproic acid). This results in a HIGHER concentration of FREE (unbound)
drug, which is the pharmacologically active form. This increases the risk of drug
toxicity even at "normal" total drug levels. The NP must: (1) Monitor free drug
levels when available, (2) Watch for signs of toxicity, (3) Consider dose reduction.
Cirrhosis further complicates this by reducing hepatic metabolism and drug
clearance.
2. Which of the following routes of administration bypasses first-pass hepatic
metabolism?
A. Oral
B. Sublingual
C. Enteral via NG tube
D. Oral extended-release formulation
Answer: B
Detailed Rationale: First-pass metabolism (presystemic metabolism) occurs when
orally administered drugs are absorbed from the GI tract and transported via the
portal vein to the liver, where they are partially metabolized BEFORE reaching
systemic circulation. Routes that BYPASS first-pass metabolism include:
Sublingual, Buccal, Rectal (partially bypasses—superior hemorrhoidal vein →
portal; middle/inferior → systemic), Intravenous, Intramuscular, Subcutaneous,
Transdermal, and Inhalation. Sublingual administration drains directly into the
superior vena cava via the sublingual vein, completely bypassing the liver.
3. A medication has a half-life of 8 hours. How long will it take to reach
approximately 94% steady-state concentration with consistent dosing?
A. 8 hours
B. 16 hours
C. 24 hours
D. 32-40 hours (4-5 half-lives)
pg. 2
,3
Answer: D
Detailed Rationale: Steady-state concentration is reached after approximately 4-5
half-lives, regardless of the dosing interval or dose. With a half-life of 8 hours: 1
half-life (8 hrs) = 50%, 2 half-lives (16 hrs) = 75%, 3 half-lives (24 hrs) = 87.5%, 4
half-lives (32 hrs) = 93.75%, 5 half-lives (40 hrs) = 96.875%. This principle is critical
for: (1) Determining when to assess full therapeutic effect, (2) Timing of drug level
monitoring (trough levels at steady state), (3) Frequency of dose titration.
4. A patient with renal impairment (CrCl 25 mL/min) is prescribed a medication
that is primarily excreted unchanged by the kidneys. The NP should:
A. Prescribe the standard dose
B. Reduce the dose and/or extend the dosing interval
C. Increase the dose due to decreased absorption
D. Switch to an IV formulation
Answer: B
Detailed Rationale: Medications primarily excreted unchanged by the kidneys
(e.g., many antibiotics [aminoglycosides, vancomycin, beta-lactams], digoxin,
gabapentin, metformin) require dose adjustment in renal impairment to prevent
drug accumulation and toxicity. The NP should: (1) Calculate CrCl (Cockcroft-
Gault) or eGFR, (2) Consult prescribing information for renal dose adjustments, (3)
Reduce the dose, extend the dosing interval, or both. Continuing standard dosing
(A) risks toxicity. Switching to IV (D) does not address the excretion problem.
5. A cytochrome P450 (CYP450) enzyme INDUCER will have what effect on a
substrate medication metabolized by that enzyme?
A. Increase the serum concentration of the substrate
B. Decrease the serum concentration and therapeutic effect of the substrate
C. Have no effect on the substrate
D. Increase the half-life of the substrate
Answer: B
pg. 3
, 4
Detailed Rationale: CYP450 INDUCERS (e.g., Rifampin, Phenytoin, Carbamazepine,
Phenobarbital, St. John's Wort, chronic alcohol) INCREASE the activity of CYP
enzymes, leading to INCREASED metabolism and DECREASED serum
concentration of substrate drugs. This can result in therapeutic failure. Examples:
Rifampin + oral contraceptives = contraceptive failure; Phenytoin + Warfarin =
decreased anticoagulation. CYP450 INHIBITORS (e.g., Azole antifungals,
Macrolides, Grapefruit juice, Cimetidine) DECREASE metabolism, leading to
INCREASED substrate concentrations and potential toxicity.
6. Which of the following best describes a competitive antagonist?
A. Binds to the same receptor site as the agonist and can be overcome by
increasing the agonist concentration
B. Binds irreversibly to the receptor
C. Binds to a different site and alters receptor function
D. Activates the receptor to produce a partial response
Answer: A
Detailed Rationale: A COMPETITIVE ANTAGONIST: (1) Binds to the SAME receptor
site as the agonist, (2) Can be overcome (surmounted) by increasing the
concentration of the agonist (shifts the dose-response curve to the right without
reducing maximum effect), (3) Example: Naloxone at opioid receptors. Non-
competitive antagonists (B) bind irreversibly or to a different site, reducing the
maximum response. Partial agonists (D) activate the receptor but produce a
submaximal response even at full receptor occupancy.
7. A loading dose of a medication is administered to:
A. Reduce side effects
B. Achieve therapeutic drug levels more rapidly
C. Increase the half-life of the drug
D. Decrease the volume of distribution
Answer: B
pg. 4
NURS 6521N ADVANCED PHARMACOLOGY
Comprehensive Final Exam Study Guide | Original
Practice Questions 2025/2026 Edition
COURSE OVERVIEW & KEY CONTENT AREAS
Advanced Pharmacology for APRNs typically covers:
1. Pharmacokinetics & Pharmacodynamics
2. Autonomic Nervous System Drugs
3. Cardiovascular & Renal Pharmacology
4. Endocrine Pharmacology
5. Anti-Infective Agents
6. Central Nervous System Drugs
7. Oncology & Immunopharmacology
8. Special Populations (Pediatrics, Geriatrics, Pregnancy)
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS
Questions 1-20
1. A 68-year-old patient with cirrhosis and hypoalbuminemia is prescribed a
highly protein-bound medication. The nurse practitioner understands that the
free (active) drug concentration will be:
A. Decreased due to increased protein binding capacity
B. Increased due to reduced albumin available for protein binding
C. Unchanged because protein binding does not affect drug activity
D. Decreased because the liver metabolizes the drug more rapidly
Answer: B
pg. 1
,2
Detailed Rationale: Hypoalbuminemia (low serum albumin) reduces the number
of protein-binding sites available for highly protein-bound drugs (e.g., phenytoin,
warfarin, valproic acid). This results in a HIGHER concentration of FREE (unbound)
drug, which is the pharmacologically active form. This increases the risk of drug
toxicity even at "normal" total drug levels. The NP must: (1) Monitor free drug
levels when available, (2) Watch for signs of toxicity, (3) Consider dose reduction.
Cirrhosis further complicates this by reducing hepatic metabolism and drug
clearance.
2. Which of the following routes of administration bypasses first-pass hepatic
metabolism?
A. Oral
B. Sublingual
C. Enteral via NG tube
D. Oral extended-release formulation
Answer: B
Detailed Rationale: First-pass metabolism (presystemic metabolism) occurs when
orally administered drugs are absorbed from the GI tract and transported via the
portal vein to the liver, where they are partially metabolized BEFORE reaching
systemic circulation. Routes that BYPASS first-pass metabolism include:
Sublingual, Buccal, Rectal (partially bypasses—superior hemorrhoidal vein →
portal; middle/inferior → systemic), Intravenous, Intramuscular, Subcutaneous,
Transdermal, and Inhalation. Sublingual administration drains directly into the
superior vena cava via the sublingual vein, completely bypassing the liver.
3. A medication has a half-life of 8 hours. How long will it take to reach
approximately 94% steady-state concentration with consistent dosing?
A. 8 hours
B. 16 hours
C. 24 hours
D. 32-40 hours (4-5 half-lives)
pg. 2
,3
Answer: D
Detailed Rationale: Steady-state concentration is reached after approximately 4-5
half-lives, regardless of the dosing interval or dose. With a half-life of 8 hours: 1
half-life (8 hrs) = 50%, 2 half-lives (16 hrs) = 75%, 3 half-lives (24 hrs) = 87.5%, 4
half-lives (32 hrs) = 93.75%, 5 half-lives (40 hrs) = 96.875%. This principle is critical
for: (1) Determining when to assess full therapeutic effect, (2) Timing of drug level
monitoring (trough levels at steady state), (3) Frequency of dose titration.
4. A patient with renal impairment (CrCl 25 mL/min) is prescribed a medication
that is primarily excreted unchanged by the kidneys. The NP should:
A. Prescribe the standard dose
B. Reduce the dose and/or extend the dosing interval
C. Increase the dose due to decreased absorption
D. Switch to an IV formulation
Answer: B
Detailed Rationale: Medications primarily excreted unchanged by the kidneys
(e.g., many antibiotics [aminoglycosides, vancomycin, beta-lactams], digoxin,
gabapentin, metformin) require dose adjustment in renal impairment to prevent
drug accumulation and toxicity. The NP should: (1) Calculate CrCl (Cockcroft-
Gault) or eGFR, (2) Consult prescribing information for renal dose adjustments, (3)
Reduce the dose, extend the dosing interval, or both. Continuing standard dosing
(A) risks toxicity. Switching to IV (D) does not address the excretion problem.
5. A cytochrome P450 (CYP450) enzyme INDUCER will have what effect on a
substrate medication metabolized by that enzyme?
A. Increase the serum concentration of the substrate
B. Decrease the serum concentration and therapeutic effect of the substrate
C. Have no effect on the substrate
D. Increase the half-life of the substrate
Answer: B
pg. 3
, 4
Detailed Rationale: CYP450 INDUCERS (e.g., Rifampin, Phenytoin, Carbamazepine,
Phenobarbital, St. John's Wort, chronic alcohol) INCREASE the activity of CYP
enzymes, leading to INCREASED metabolism and DECREASED serum
concentration of substrate drugs. This can result in therapeutic failure. Examples:
Rifampin + oral contraceptives = contraceptive failure; Phenytoin + Warfarin =
decreased anticoagulation. CYP450 INHIBITORS (e.g., Azole antifungals,
Macrolides, Grapefruit juice, Cimetidine) DECREASE metabolism, leading to
INCREASED substrate concentrations and potential toxicity.
6. Which of the following best describes a competitive antagonist?
A. Binds to the same receptor site as the agonist and can be overcome by
increasing the agonist concentration
B. Binds irreversibly to the receptor
C. Binds to a different site and alters receptor function
D. Activates the receptor to produce a partial response
Answer: A
Detailed Rationale: A COMPETITIVE ANTAGONIST: (1) Binds to the SAME receptor
site as the agonist, (2) Can be overcome (surmounted) by increasing the
concentration of the agonist (shifts the dose-response curve to the right without
reducing maximum effect), (3) Example: Naloxone at opioid receptors. Non-
competitive antagonists (B) bind irreversibly or to a different site, reducing the
maximum response. Partial agonists (D) activate the receptor but produce a
submaximal response even at full receptor occupancy.
7. A loading dose of a medication is administered to:
A. Reduce side effects
B. Achieve therapeutic drug levels more rapidly
C. Increase the half-life of the drug
D. Decrease the volume of distribution
Answer: B
pg. 4
